ANZCTR search results

Medications can sometimes cause serious problems, like ending up in hospital or even death. People living in rural and deprived areas are more vulnerable to these problems. We aim to work with rural consumers and healthcare providers to develop a new computer support tool that will help health professionals find people who might be at risk because of their medicines. Then, doctors, nurses, and pharmacists can check these medications and make necessary changes to keep rural Australians safe.

This pilot study will test whether a single faecal microbiota transplantation (FMT) enema can be delivered safely and feasibly to adults with alcohol use disorder and compensated alcohol-associated liver disease. Participants will be randomly allocated to receive either FMT or a matched placebo enema and will be followed for 12 weeks, with extended safety follow-up to 6 months. The main outcomes are feasibility of conducting the trial, including recruitment, retention, intervention completion and biospecimen collection, and safety/tolerability, including adverse events and serious adverse events. The study will also explore changes in alcohol use, craving, liver-related measures and gut microbiome features. This trial is designed to inform whether a larger definitive trial of microbiome-targeted therapy in alcohol-related disease is justified.

Compared to other myopia interventions, Repeated Low-level Red-Light therapy has shown superior effectiveness in pre-myopia and high myopia as well as, small but significant shortening of axial length. Currently, there is no evidence that once-daily RLRL therapy is as effective as twice-daily standard therapy. If once-daily treatment proves equally effective, it would reduce exposure by half, potentially minimising long-term side effects.

This study is testing whether a surgical robot called the Toumai® MT-1000 can be used to perform bowel (colorectal) and abdominal wall surgery safely and effectively at Concord Repatriation General Hospital, where it has been newly introduced. Who is it for? You may be eligible for this study if you are an adult patient undergoing an elective colorectal or abdominal wall reconstructive procedure, including patients who have been diagnosed with cancer and are suitable for minimally-invasive surgery. Study details Participants will have their operation performed using the robot by experienced, specially credentialled robotic surgeons, with the operation itself unchanged from what they would normally have. Participants complete short quality-of-life questionnaires before surgery and at 6 weeks, 3 months and 6 months afterwards, while the research team collects routine information about the operation and recovery from the medical record. The two main things being measured are how often the robotic operation needs to be converted to open surgery (a measure of feasibility) and how often serious complications occur (a measure of safety), with results for bowel cancer patients compared against similar past patients who had standard keyhole (laparoscopic) surgery. It is hoped that findings from this study will help inform clinicians and researchers whether the Toumai® MT-1000 is a feasible and safe system for such operations.

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, characterized by the progressive formation and enlargement of fluid-filled cysts in the kidneys, which can lead to chronic kidney disease and ultimately end-stage renal disease (ESRD). Investigational Product: GV-100 Dose Form: Suspension Route of Administration: Oral This randomized, placebo-controlled study is designed to evaluate safety and tolerability, as well as pharmacokinetics (PK) and pharmacodynamics (PD), and is conducted in two parts: Part 1 (Single Ascending Dose [SAD]), Part 2 (Multiple Ascending Dose [MAD]).

When men have surgery for a blocked prostate (called TURP), they often notice that they no longer ejaculate during orgasm. This is commonly assumed to be because semen travels backwards into the bladder instead of forwards, a condition called retrograde ejaculation. However, it is possible that the cause is actually that semen is not produced at all during orgasm (anejaculation). These two conditions look the same from the outside but have different implications, particularly for men who wish to have children in the future. This study will use a simple urine test after orgasm to objectively determine which of these two conditions is occurring in men who have had TURP. It will also assess whether this urine test is practical enough to be used routinely in clinical care.

Randomised 3×3 crossover; each participant completes three fasted morning visits with unilateral EIMD (limb alternation; adequate washouts). Post-exercise breakfast (within 30–45 min): whole eggs, egg whites, or whey (protein-matched, macronutrient and energy matched). Outcomes: VAS soreness and strength recovery over 72 h recovery window, bio-markers of muscle damage (CK) and mechanisms (post-prandial amino acid profiles and fatty acid profiles in a subset of participants).

Brief description of the study purpose This study aims to find out whether simple text message reminders from a general practitioner (GP) can encourage young adults to learn about and receive the human papillomavirus (HPV) vaccine, which helps prevent certain cancers. Who is it for? This study is for young adults aged 18 to 25 who are patients at a participating GP clinic and are eligible for a catch-up HPV vaccination but have not yet completed it. Study details Participants will be randomly assigned to one of two groups. One group will receive three text messages from their GP over three months, encouraging them to learn about and consider getting the HPV vaccine. The other group will continue with usual care for six months and will then receive the same text messages later. These messages are sent directly to the participant’s mobile phone through GP clinic software. The study will also monitor whether messages are successfully delivered and whether participants respond. Routine health records from the GP clinic may be used to determine whether participants go on to receive the HPV vaccine. Medical records will be used to determine the number of participants who end up getting the recommended vaccine. Survey and interviews will be used to identify facilitators, barriers and other factors for future scale-up of the intervention. It is hoped that this research will show whether simple, low-cost text message reminders from GPs can increase HPV vaccination rates and help prevent HPV-related cancers in young adults.

This project will pilot Story-ABI-lity, a novel, co-designed speech pathology intervention for adults with traumatic brain injury (TBI). Story-ABI-lity is a manualised narrative intervention developed in collaboration with people with TBI and multidisciplinary clinicians, specifically designed for the inpatient rehabilitation context. Despite this setting providing the greatest opportunity for intensive, early intervention, there are currently no programs specifically designed to address communication impairments in hospital. Communication impairments following TBI are often persistent and limit the ability to participate in conversations and communicate needs clearly, impacting engagement in rehabilitation and long-term social relationships. Story-ABI-lity targets everyday narratives by integrating metacognitive strategy training with structured storytelling intervention, grounded in established theoretical and evidence-based frameworks.

Cohorts 2 and 3 are double-blind, randomized, placebo-controlled studies evaluating the safety, tolerability, and PK of multiple SCY-770 doses in 8 participants (3:1 randomization). Progression to Cohort 3 depends on SRC review of Cohort 2 data. Cohort 3 uses sentinel dosing, with 2 participants dosed first, followed by the remaining 6 participants if safety is confirmed. Cohort 2 – SCY-770 750mg QD for 7 days Cohort 3 – SCY-770 500mg BID for 6 days and SCY-770 500mg QD on Day 7: